Vir Biotechnology
204 hedge funds and large institutions have $2.09B invested in Vir Biotechnology in 2022 Q1 according to their latest regulatory filings, with 47 funds opening new positions, 84 increasing their positions, 44 reducing their positions, and 49 closing their positions.
91% more repeat investments, than reductions
Existing positions increased: 84 | Existing positions reduced: 44
62% more call options, than puts
Call options by funds: $16.7M | Put options by funds: $10.3M
1.66% more ownership
Funds ownership: 59.67% → 61.33% (+1.7%)
4% less first-time investments, than exits
New positions opened: 47 | Existing positions closed: 49
3% less funds holding
Funds holding: 210 → 204 (-6)
36% less capital invested
Capital invested by funds: $3.25B → $2.09B (-$1.16B)
43% less funds holding in top 10
Funds holding in top 10: 7 → 4 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$112M |
| 2 |
State Street
Boston,
Massachusetts
|
+$49.4M |
| 3 |
GF
Gates Foundation
Seattle,
Washington
|
+$26.1M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
+$14M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$12.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$86M |
| 2 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
-$36M |
| 3 |
Capital International Investors
Los Angeles,
California
|
-$34.9M |
| 4 |
Morgan Stanley
New York
|
-$19M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$17.5M |
VIR Hedge Fund Activity: Q1 2022 in Review
204 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Vir Biotechnology (VIR) for Q1 2022, worth a combined $2.09B — down 36% from $3.25B a quarter earlier.
Sellers outnumbered buyers: 49 funds closed out of VIR and 47 opened new positions — a net loss of 2 holders — while 44 trimmed existing stakes and 84 added.
The largest buyer was Millennium Management, adding an estimated $112M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $86M sold.
- 204 institutional investors held Vir Biotechnology (VIR) as of Q1 2022, down from 210 in Q4 2021.
- Funds reported $2.09B of Vir Biotechnology stock for Q1 2022, down 36% quarter-over-quarter.
- 47 funds opened new Vir Biotechnology positions in Q1 2022 and 49 closed out, a net change of -2 holders.
- The largest Vir Biotechnology buyer in Q1 2022 was Millennium Management, an estimated $112M added.
- The largest Vir Biotechnology seller in Q1 2022 was Point72 Asset Management, an estimated $86M sold.
Based on aggregated 13F filings for Q1 2022.